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Abstract
Background: Sarcomas are rare tumors (1-2% of all cancers) of mesenchymal origin that may develop in soft tissues 
and viscera. Since the International Classification of Disease (ICD) attributes visceral sarcomas (VS) to the organ of 
origin, the incidence of sarcoma is grossly underestimated. The rarity of the disease and the variety of histological types 
(more than 70) or locations account for the difficulty in acquiring sufficient personal experience. In view of the above 
the European Commission funded the project called Connective Tissues Cancers Network (CONTICANET), to improve 
the prognosis of sarcoma patients by increasing the level of standardization of diagnostic and therapeutic procedures 
through a multicentre collaboration.
Methods/Design: Two protocols of epidemiological researches are here presented. The first investigation aims to 
build the population-based incidence of sarcoma in a two-year period, using the new 2002 WHO classification and the 
"second opinion" given by an expert regional pathologist on the initial diagnosis by a local pathologist. A three to five 
year survival rate will also be determined. Pathology reports and clinical records will be the sources of information.
The second study aims to compare the effects on survival or relapse-free period - allowing for histological subtypes,
clinical stage, primary site, age and gender - when the disease was treated or not according to the clinical practice
guidelines (CPGs).
Discussion: Within CONTICANET, each group was asked to design a particular study on a specific objective, the 
partners of the network being free to accept or not the proposed protocol. The first protocol was accepted by the 
other researchers, therefore the incidence of sarcoma will be assessed in three European regions, Rhone-Alpes and 
Aquitaine (France) and Veneto (Italy), where the geographic distribution of sarcoma will be compared after taking into 
account age and gender. The conformity of the clinical practice with the recommended guidelines will be investigated 
in a French (Rhone Alps) and Italian (Veneto) region since the CPGs were similar in both areas.
Background
Epidemiological challenges of sarcoma
Sarcomas are rare tumors (1-2% of all cancers) originat-
ing from connective tissue, skin, retroperitoneum, bone,
and viscera; Kaposi's sarcoma is usually excluded or
reported apart. In the Venetian Tumour Registry (VTR),
the incidence data (per 100,000) from 2000 to 2004 for
sarcomas are shown in Table 1.
Tumor registry data derive from a cross-check among
three different sources: biopsy records of pathology
departments, hospital discharge forms, and death certifi-
cates. The latter sources use the International Classifica-
tion of Disease (ICD) that attributes visceral sarcomas
(VS) to the organ of origin. The incidence of sarcomas is
thus grossly underestimated.
Tumor classifications have become an integral part of
modern oncology and provide pathologists with guide-
lines to facilitate diagnostic and prognostic reproducibil-
ity.
In late 2002, the World Health Organization (WHO)
published a new classification of sarcoma. Since it repre-
sents a broad consensus view, it has gained widespread
acceptance. The four most significant conceptual
advances have been: (i) the formal recognition that mor-
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phologically benign lesions (such as cutaneous fibrous
histiocytoma) may very rarely metastasize; (ii) the general
acceptance that most pleomorphic sarcomas can be
meaningfully sub-classified and that the so-called malig-
nant fibrous histiocytoma is not a definable entity, but
instead represents a wastebasket of undifferentiated pleo-
morphic sarcomas, accounting for no more than 5% of
adult soft tissue sarcomas (STS); (iii) the acknowledge-
ment that most lesions formerly known as haemangio-
pericytoma show no evidence of pericytic differentiation
and, instead, are fibroblastic in nature and form a mor-
phological continuum with solitary fibrous tumors; and
(iv) the increasing appreciation that the derivative cell
type(s) of most STS (histogenesis) is unknown and,
hence, an increasing number of tumors are placed in the
"uncertain differentiation" category [1].
To our knowledge, there are few studies that have
reported morphology-specific tabulations of sarcoma,
using the 2002 WHO classification criteria. Toro et al. [2]
analyzed the 1978-2001 Surveillance, Epidemiology and
End Results program incidence rates of sarcoma regard-
less of primary site, except from bones and joints, using
the 2002 WHO classification criteria. There were 26,758
cases available for the analysis. Almost half (47.9%) of all
sarcomas developed in soft tissues, 14.0% in the skin and
7.0% in the uterus. Overall, the incidence rates were high-
est among black women (6.26/100,000 person-years) and
lowest among white women (4.60/100,000). Age adjusted
rates increased at 1.2% and 0.8% per calendar year among
white males and females, respectively, both trends being
statistically significant, while rates among blacks declined
slightly. Total sarcoma rates rose exponentially with age.
Rates for both uterine leiomyosarcoma and dermatofib-
rosarcoma increased rapidly during the childbearing
years, peaking at about the age of 40 and 50 respectively.
The incidence patterns of sarcoma varied markedly by
histological type, underpinning the notion that these
tumors may be etiologically distinct.
Diagnostic challenges
Although sarcomas are rare cancers, they include more
than 70 different histological subtypes. Furthermore, dif-
ference in diagnostic criteria as well as the use of new
techniques (i.e. immunohistochemistry, rt-PCR, molecu-
lar genetics, genomics) complicate their histotype defini-
tion.
There is a considerable subjective variability among
physicians in making observations on even the simplest
of events. For instance, in clinical studies involving
assessment of imaging methods like X-Rays, ultrasounds,
and CT scans, the value of the study can be better
assessed if measures of variability are evaluated and
reported. Histological examinations are also imaging
techniques. When it comes to cancer, a pathological diag-
nosis is the "gold standard" that indicates the presence or
absence of the malignancy, the type of cancer, and its
classification. Due to the fact that therapeutic decisions
are based on the presumed reliability of the pathology
diagnosis, a misdiagnosis can result in unnecessary,
harmful and aggressive therapy or inadequate treatment.
Unfortunately, medical studies over the last two decades
have demonstrated that this gold standard is not consis-
tently reliable for sarcoma. In fact, multiple studies have
demonstrated discrepancy rates of up to 30% with an
average of approximately 10%. A "discrepancy" happens
when one pathologist renders a diagnosis and another
pathologist looks at the same material and provides a dif-
ferent opinion [3]. For example, a major discrepancy was
found in 25% of 266 cases of soft tissue lesions reviewed
by an expert. Of these discrepancies, 45% consisted of
benign lesions diagnosed as sarcomas, and 23% were sar-
comas diagnosed as benign tumors [4]. Obtaining a
wrong pathological report is not limited to the U.S. Other
Table 1: Incidence data (per 100,000) for sarcomas, 2000-2004.




180 0.6 3.9 3.3 2.6
Kaposi's skin 
(males)
48 0.1 1.0 0.8 0.6
Soft tissue 
sarcoma (females)
136 0.5 2.8 2.2 1.8
Kaposi's skin 
(females)
15 0.1 0.3 0.1 0.1
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countries have found similar problems. For example, in
the United Kingdom, 413 cases of sarcoma were reviewed
and the diagnosis was confirmed in only 76% of instances.
The study concluded that "second opinion is essential in
cases of presumed sarcoma ... to ensure that appropriate
treatment is selected." [5].
In order to analyse the impact of modern sarcoma clas-
sification criteria, Daugaard [6] reviewed the pathological
material from 281 extremity STS. The cases were origi-
nally diagnosed between 1972 and 1994, and the most
frequent diagnoses were then malignant fibrous histiocy-
toma (MFH) (26%), liposarcoma (21%), fibrosarcoma
(11%), and leiomyosarcoma (10%). After reclassification,
the proportions had changed significantly, with the larg-
est group now being leiomyosarcomas (20%), liposarco-
mas (17%), synovial sarcomas (14%), and sarcomas "Not
Otherwise Specified" (NOS) (11%). The original diagno-
sis was changed in 57% of the cases; in particular, the
number of fibrosarcomas was reduced from 32 to 6, and
MFHs from 72 to 2, with 22 renamed as myxofibrosarco-
mas; 20 (7%) were found not to be sarcomas.
The vast majority of pathologists' diagnoses are correct.
However, a minority of cases benefit from a second opin-
ion. One factor to consider is how rare the cancer is. If it
is rare, chances are that a pathologist has not seen many
of this type of tumor. Although the overall percentage of
affected cases is not large, the consistent rate of discrep-
ant diagnosis uncovered by second opinion surgical
pathology may have an enormous human and financial
impact. Accordingly, the authors recommend that review
of the original histological material should be undertaken
prior to the institution of a major therapeutic endeavour
[7].
Therapeutic challenges
Qu a l i t y  o f  ca r e  is  d e f i n ed  b y  WH O  as  " a  p r oc e s s  t h a t
allows one to guarantee to each patient the range of diag-
nostic and therapeutic procedure that will ensure the best
outcome in terms of health in conformity with Evidence-
Based Medicine, in the most costs effective manner, at
the lesser iatrogenic risk and for the highest satisfaction
in terms of procedure for the patient, outcomes and
human relationships within the health care system".
According to [8], this process involves an evaluation of:
• structure (characteristics of the care providers, their
tools and resources, and the physical/organizational set-
ting);
• process (both interpersonal and technical aspects of
the treatment process);
• outcome (change in the patient's symptoms and func-
tioning).
Geographic variation of medical procedure utilization
is a well known issue in industrialized countries [9-14].
The characteristics of hospital structures could be
responsible for variations in practices, sometimes induc-
ing large differences in the consumption of resources
[15]. Another factor is the big size of the institution which
seems to promote the use of more sophisticated tech-
niques [16]. The determinants of medical decision-mak-
ing remain to be evaluated and specified. Since patients
may receive care which results in adverse rather than
beneficial results with more adverse than beneficial
effects, professional practice variations represent an
essential area of research.
In order to prove the relationship between differences
in mortality and differences in medical practice or medi-
cal organisations, a suitable observational ground seems
to be the study of rare tumours, such as sarcomas. The
rarity of the disease, the variety of histological types or
locations and the heterogeneity of prognostic factors
associated with local or distant spread, account for the
difficulty in acquiring sufficient personal experience.
Moreover, the lack of graduate or post-graduate medical
teaching makes it difficult for physicians outside centres
of excellence to provide appropriate sarcoma manage-
ment. Every stage of the treatment remains controversial,
and this is why multidisciplinary co-ordination is essen-
tial. A number of scientific publications have suggested
the existence of a causal link between medical practices
and patient outcome [17]. In France (Rhone-Alpes
region), a retrospective analysis of the medical records of
100 patients with localized STS (stage TxNxM0) revealed
significant correlations between:
• local relapse and: quality of resection (p = .01); macro-
scopic extent of surgery (p = .002); subspecialty of the
surgeon (p = .03); type of hospital (p = .02); review of
patient file by multidisciplinary committee before surgery
(p = .02); management in the cancer network (p = .02);
conformity of radiotherapy with clinical practice guide-
lines (CPGs) (p = .007);
• metastatic relapse and: histological grade (p = .008);
multidisciplinary committee decision after surgery (p =
0.04)]; and management in the cancer network (p = .02)
[18].
The retrospective nature of this study did not appear
sufficient to ensure a satisfactory conclusion; thus a pro-
spective study design will be adopted, and investigation
will be conducted on a larger scale in order to determine
the impact of each prognostic factor on patient survival.
Research objectives
In view of all the above, the European Commission has
recently approved the project CONnective TIssues CAn-
cers NETwork (CONTICANET), which aims to improve
the prognosis of sarcoma patients by increasing the level
of standardisation of diagnostic and therapeutic proce-
dures (Additional File 1). The study received formalMastrangelo et al. BMC Public Health 2010, 10:188
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approval by the Ethical Committee of the Padua Univer-
sity Hospital.
Within the frame of the CONTICANET project, we
will collect prospectively a population-based series of
STS and VS cases in the Veneto Region during 2007 and
2008 (two years), with the aim to:
• build up the population-based incidence of sarcoma
in a two-year period (2007-2008), using the new WHO
classification of 2002 and a "second opinion" given by an
expert regional pathologist about the diagnosis of a local
pathologist. The three to five year survival period will
also be ascertained (Study 1);
• the second study aims to compare in patients with
STS, VS, and gastro-intestinal stromal tumors (GIST, a
histological type of VS) the effects on survival or relapse-
free period - allowing for histological subtypes, stage, pri-
mary site, age and gender - when the disease was treated
or not in compliance with CPGs (Study 2).
Methods/Design
Study 1. Estimating the population-based incidence of 
sarcoma (2007-2008), the three- to five-year survival rate, 
and the causes of death
Activities undertaken before the date of issue of the pres-
ent protocol are described by using passive voice and past
tense. The active voice and present (or future) tense is
used for any repetitive technical activity, as well as for any
administrative procedure, that is being followed in order
to achieve the study objectives.
Case definition
Cases will be subjects:
• of both genders and any age, residing in Veneto;
• with histologically proven malignant sarcoma (classi-
fication in Additional File 2), diagnosed as a first cancer
during 2007 and 2008, (despite the fact that distant
metastasis were present at initial diagnosis).
Osteosarcoma, sarcomatoid carcinoma, mesothelioma,
neuroblastoma, paraganglioma, and mixed (epithelial and
mesenchymal) tumors of the female genital tract will be
excluded, as well as patients (any histology) with a relapse
of sarcoma in the observation period.
Scrutinizing the pathology network
The principal source of cases will be the regional network
of pathologists. Three expert leaders for second opinion
on sarcoma in Veneto agreed to support the study.
BARRIERS In order to achieve the study objective, all
the regional Pathology Departments were identified and
the following barriers were overcome:
• lack of cooperation;
• obstacles due to confidentiality and internal rules;
• type of data storage and data processing;
• type of morphological classification and codes for
case classification;
• procedures for case identification and sorting.
Lack of cooperation
All the data needed were located in the pathology
records. In an automated environment, reporting could
be as simple as a few keystrokes. Unfortunately, in Veneto
an automated reporting of pathological diagnoses to a
single archive does not exist, thus rendering our study
heavily dependent on the actions of very busy patholo-
gists. Therefore, the pathologists of Veneto were person-
ally invited to team up with the expert leaders to whom
they apply for the second opinion for sarcoma. A person
was assigned to clinical monitoring in order to help the
collection of cases from the Pathology departments every
three months.
Obstacles by confidentiality legislation and internal
rules
The clearance from the Ethical Committee was
obtained along with the support of the managing tams of
all the Local Health Units (LHUs) in Veneto. An informed
consent will be requested from all patients for data stor-
age and follow-up.
Type of morphological classification and codes for
cases classification
All pathologists agreed to use the morphological classi-
fication of WHO in 2002 [19] and the SNOMED codes
for sarcoma in their daily practice. Classification and
codes are reported in Additional File 2.
Procedures for cases identification and sorting
In the pathology departments of Veneto, computerized
data are processed by using different software packages:
Armonia, WindoPath, APSIS, and others. All depart-
ments in Veneto have to be scrutinized.
Second opinion diagnosis
The Section of Pathology (Department of Oncology
and Surgery, University of Padua) and the Department of
Pathology (Treviso Regional Hospital), perform both pri-
mary cancer diagnosis and second opinion diagnosis. The
primary diagnoses of Padua will be reviewed by Treviso
experts and vice versa.
Scrutinising other archives
As already known, the incident cases of sarcoma will be
searched through parallel scrutiny of multiple indepen-
dent sources: network of pathologists and archives of
hospital discharges.
Archive of hospital discharge records The archive of
hospital discharge forms will be scrutinised through a
coordinated action with the Regional Epidemiological
Service of the Veneto Region (SER). All admissions with
ICD-9 codes 171, 158 and 176 among discharge diagno-
ses (all diagnostic positions) will be extracted four times/
year from the electronic archives of hospital discharge
records available at SER. Repeated admissions of the
same subject will be identified, and prevalent cases (sub-
jects hospitalised with the relevant diagnoses in 2005-
2006) will be excluded. The list of subjects identified byMastrangelo et al. BMC Public Health 2010, 10:188
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discharge records will be sent to the clinical monitor to
ascertain the diagnosis in those not retrieved through the
other sources. If the patient was not already known, the
clinical monitor will report the information forms to the
physician in charge of the epidemiological study.
Tracing clinical records All medical records regarding
the above patients will be traced and photocopied from
the relevant hospital offices.
Statistical analysis
The incidence will be calculated by age, gender, main
nosological group (STS and VS), primary site and the his-
tological type of the tumor. The incidence rates will be
age-standardised with the direct method, using the
World and European populations as standard. Survival
rates will be calculated by the Kaplan-Meier method [20].
A capture-recapture approach will be used to determine
and improve accuracy in estimating frequency of STS and
VS [21].
Study 2. Evaluation of medical practices and their impact 
on the management of a rare malignant tumor: an 
application for the management of sarcoma in the Veneto 
region
Case definition
We will include patients:
• of both genders;
• residing in Veneto;
• older than 18 years at initial diagnosis;
• with histologically proven STS, VS, or GIST, diag-
nosed and/or treated from 2007 to 2008, without distant
metastasis at initial diagnosis. Only cases of localized or
locally advanced STS, VS, or GIST will be selected (dis-
ease stage: TxNxM0).
We will exclude:
• patients seen for a relapse of sarcoma in the observa-
tion period;
• patients whose treatment had not been managed in
Veneto.
Study size
In the study by [18], cases of local relapse after treatment
were 22% (= 9/39) or 44% (= 27/61) in sarcoma patients
with or without multidisciplinary committee before/after
surgery respectively (Table 2).
Therefore, the computation of the study size assumes
that:
• the differences between the two proportions (namely
22% and 44%) corresponded to the expected effect;
• the significance criterion (alpha) is set at 0.05;
• the test is 2-tailed, which means that an effect in
either direction will be interpreted.
Based on these assumptions, the study should include
200 (or 150) patients in order to have a 89% (or 78%)
power to yield a statistically significant result.
Collection of clinical data
Surgeons, oncologists and pathologists will be
approached (in ad hoc meetings) for consent to produce
hospital records of patients under their care for the pur-
pose of this study.
All medical records of each patient will be photocopied,
and data on clinical history and treatment will be col-
lected from medical records during the course of the
study. Information to be collected on a standardised form
includes:
• registry data of the patient, identification of hospital
and physicians in charge;
• clinical features, imaging studies, stage of the disease;
• date and methods of the initial diagnosis (before sur-
gery), histology of surgical specimen and histology of
metastases;
• description of the initial surgical operation, particular
techniques (limb perfusion, brachitherapy), surgical
removal of metastases;
• radiotherapy: characteristics and response;
• chemotherapy: characteristics and response;
• relapse: date, diagnosis, and topography;
• surgical intervention after relapse including particular
techniques and removal of metastases (histology of
metastases);
• radiotherapy after relapse: characteristics and
response; chemotherapy after relapse: characteristics and
response;
• patients follow-up and eventual date and cause of
death;
• analysis of the process: compliance with guidelines;
multidisciplinary coordination at different steps (before







Yes 9 30 39
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biopsy, before surgery, before adjuvant therapy, at first
and following relapses).
Compliance with Clinical Practice Guidelines (CPGs)
While other sections of the above form will be completed
by a single clinical research assistant, the last section of
the questionnaire (regarding compliance) will be col-
lected by a single investigator. Observations made by a
single observer will avoid inter-observer reproducibility
biases. Reproducibility in the analysis of decisions across
patients will be evaluated during the course of the study
by control from pre-selected experts and by reassessment
of random records from the same expert blinded to the
results of the previous analysis.
The CPGs is a nationwide project of the Italian
National Research Council (CNR). The first volume of
the standards, option and recommendations (SOR) for
the clinical management of cancer was published in 2003
[22]. These SOR were accepted with minor discrepancy
by the oncologists of the Veneto Region. The clinical final
release was diffused in 2004.
Criteria for optimal initial examination and diagnosis 
(i) Clinical size and depth of the mass must be recorded;
(ii) computed tomography (CT) is required for abdominal
localization, or magnetic resonance imaging (MRI) of the
mass for limb localization; (iii) chest radiograph or CT
scan is required to identify metastases; and (iv) pre-oper-
ative biopsy (incisional or needle) should be performed,
preferably by the surgeon in charge of future surgical
management. Exception is made for small tumors <3 cm,
where excisional biopsy is accepted.
Criteria for optimal surgical management Whenever
possible, primary surgery should perform wide excision
with 1-2 cm margins. For high-grade lesions, large (>3
cm) tumors, or deep-seated tumors, surgery alone is
acceptable only in case of amputation or compartimental
resection with negative histological margins (R0). Wide
excision alone, with no adjuvant treatment, is acceptable
only for superficial, small (<3 cm) and low-grade lesions.
Histologically positive margins (R1) or incomplete exci-
sion (R2) have to be considered inadequate, and should
be followed by further appropriate treatment (further
surgery or adjuvant therapy if formal review by a multi-
disciplinary sarcoma committee considers surgery non-
feasible). TNF-based isolated limb perfusion can be pro-
posed as neo-adjuvant treatment in patients candidates
for amputation or as palliative care.
Criteria for histopathological report The following
parameters should be reported: i) histological type
(according to WHO system); ii) histological grade; iii) size
of the tumor; iii) status of resection margins (minimum
distance); iv) results of ancillary studies (immuno-his-
tochemical, cytogenetic and molecular studies).
Criteria for optimal radiation therapy management 
Association between wide excision and adjuvant radia-
tion therapy should be considered the gold standard
treatment. The absence of adjuvant radiotherapy is
acceptable for superficial, small (<3 cm) and low-grade
tumors, and for limb sarcomas when amputation is per-
formed. For non-operable sarcomas, primary radiation
therapy could be an option. Optimal technical criteria
are: (i) 50 Gy delivered dose [with an additional boost of
10 Gy in case of microscopic residual tumor (R1)]; (ii) tar-
get volume to irradiate encompassing tumor bed, scars,
including draining orifices, with appropriate security
margins; and (iii) delay from surgery to radiation therapy
not exceeding 12 weeks.
Criteria for optimal chemotherapy management For
non-readily, non-operable sarcomas, primary chemother-
apy can be an option, as can radiation therapy. For readily
operable sarcomas, neo-adjuvant chemotherapy should
be performed only as part of a clinical research protocol.
In the adjuvant setting, systemic chemotherapy should be
performed only within the context of a prospective clini-
cal trial. Adjuvant chemotherapy could be performed for
patients with histologically positive margins after wide
surgery.
Criteria for optimal post-therapeutic surveillance 
There is no consensus concerning the surveillance of sar-
comas. Recommendations of the SOR are follow-up with
clinical examination every 12 weeks during the first 3
years, then every 6 months until the fifth year post-man-
agement. Clinical examination and chest radiograph or
CT scan and ultrasound examination are the prevailing
tools to identify metastases.
Statistical analysis
Overall survival will be measured from the date of diag-
nosis to the date of death or to the day of loss to follow-up
for living patients. Relapse-free survival is defined as the
interval between curative treatment and diagnosis of
relapse. Stable disease is defined as the documented pres-
ence of a non respectable tumor or residual tumor after
surgery. For these patients with stable disease, the esti-
mated relapse-free survival is 0 months. The analyses of
patterns of care and survival will be restricted to STS and
VS as a whole, or GIST.
Treatment centres (identified from the SER's records)
will be classified as follows:
• teaching hospitals attached to medical schools;
• non-teaching hospitals: the remaining regional
(Veneto) hospitals treating study patients.
Descriptive statistics such as absolute and relative fre-
quencies, mean and standard deviations (range), as well
as χ2-test, Fisher's exact test, Student's t-test, ANOVA or
Mann-Whitney U-test will be performed where appro-
priate. Time to progression and survival will be analyzed
using the Kaplan-Meier method, together with the logMastrangelo et al. BMC Public Health 2010, 10:188
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rank test [20]. For a multivariable approach, Cox propor-
tional hazard regression analysis will be used. A multivar-
iable logistic regression analysis will be used to identify
predictors of adequacy of clinical decisions with Evi-
dence-Based Medicine. The analysis will take into
account the fitting of the following factors: institution,
physician and patient. In all statistical analyses p < 0.05
will be considered to indicate statistical significance.
Discussion
Within the CONTICANET network there were nine
main activities or work packages (WP): Network Man-
agement (WP1); Network sustainability (WP2); Network
methodologies and infrastructures (WP3); Epidemiology
(WP4); Molecular characterization (WP5); Target char-
acterization, drug screening and non-clinical pharmaco-
dynamics (WP6); Clinical pharmacology, clinical phar-
maco-dynamics and pharmaco-vigilance (WP7A);
Regional therapy, including surgery and radiotherapy
(WP7B); Dissemination (WP8); and Transfer of Excel-
lence (WP9). Moreover, within each WP there were sev-
eral tasks and task groups. For example WP4
(Epidemiology) included the following research activities:
• Descriptive epidemiology;
• Molecular epidemiology;
• Determinants of medical practice;
• Education directed to medical practitioners, surgeons
and pathologists.
Each group was asked to design a particular study on a
specific objective, the partners of the network being free
to accept or not the proposed protocol.
The protocol of the above Study 1 (incidence of soft tis-
sue and visceral sarcoma) was proposed by the University
of Padua and accepted by two other partners. Therefore,
the incidence and survival of sarcoma will be ascertained
in three European regions (two French regions: Rhone-
Alpes and Aquitaine and one Italian region: Veneto). In a
collateral future study, the geographic distribution of sar-
coma according to histotype (and adjusting for age and
gender) will be compared between and within the
regions. Clustering of patients with sarcomas could allow
the establishment of hypotheses on risk factors underpin-
ning the particular spatial distributions of cases. Subse-
quently, an ecological study will be planned to investigate
whether environmental risk factors could affect the inci-
dence of sarcoma. Lastly, a case-control study will be
designed to assess the risk factors for soft tissue and vis-
ceral sarcoma and the major histological types.
The protocol of the above Study 2 (compliance of medi-
c a l  c a r e  w i t h  t h e  C P G s  f o r  s a r c o m a )  w a s  a c c e p t e d  b y
another partner. Therefore, conformity of clinical prac-
tice with the CPGs will be investigated in France (Rhone
Alps Region) and Italy (Veneto Region) since French and
Italian guidelines are similar. A collateral new study could
be planned on the cost-effectiveness analysis of compli-
ance with CPGs for sarcoma management, during the
whole clinical pathway of patients from diagnosis to
death or end of follow-up. The analysis of these relations
could be useful to advise public health policy makers on
the economic consequences of CPGs for rare tumors,
within a long term perspective.
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